EUVIMEDEUVIMED entdecken
Open Access

Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer

Chiharu Sako iD, Chong Duan iD, Kevin Maresca, Sean Kent iD, Taly Gilat Schmidt iD, Hugo J W L Aerts, Ravi B Parikh iD, George R Simon iD, Petr Jordan iD

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.24.00133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Chiharu Sako und 8 weiteren Autor:innen. Beteiligte Einrichtung: Onc.AI, San Carlos, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Deep Learning. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This study developed and validated a novel deep learning radiomic biomarker to estimate response to immune checkpoint inhibitor (ICI) therapy in advanced non–small cell lung cancer (NSCLC) using real-world data (RWD) and clinical trial data. MATERIALS AND METHODS Retrospective RWD of 1,829 patients with advanced NSCLC treated with PD-(L)1 ICIs were collected from 10 academic and community institutions in the United States and Europe. The RWD included data sets for discovery (Data Set A-Discovery, n = 1,173) and independent test (Data Set B, n = 458). A radiomic pipeline, containing a deep learning feature extractor and a survival model, generated the computed tomography (CT) response score (CTRS) applied to the pretreatment routine CT/positron emission tomography (PET)-CT scan. An enhanced CTRS (eCTRS) also incorporated age, sex, treatment line, and lesion annotations. Performance was evaluated against progression-free survival (PFS) and overall survival (OS). Biomarker generalizability was further evaluated using a secondary analysis of a prospective clinical trial (ClinicalTrials.gov identifier: NCT02573259 ) evaluating the PD-1 inhibitor sasanlimab in second or later line of treatment (Data Set C, n = 54). RESULTS In RWD Test Data Set B, the CTRS identified patients with a high probability of response to ICI with a PFS hazard ratio (HR) of 0.46 (95% CI, 0.26 to 0.82) and an OS HR of 0.50 (95% CI, 0.28 to 0.92) in the first-line ICI monotherapy cohort, after adjustment for baseline covariates including the PD-L1 tumor proportion score. In Clinical Trial Data Set C, the CTRS demonstrated an adjusted PFS HR of 1.03 (95% CI, 0.43 to 2.47) and an OS HR of 0.33 (95% CI, 0.14 to 0.91). The CTRS and eCTRS outperformed traditional imaging biomarkers of lesion size in PFS and OS for RWD Test Data Set B and in OS for the Clinical Trial Data Set. CONCLUSION The study developed and validated a deep learning radiomic biomarker using pretreatment routine CT/PET-CT scans to identify ICI benefit in advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsDeep LearningB7-H1 AntigenBiomarkers, TumorHumansMaleFemaleAgedMiddle AgedRetrospective StudiesPositron Emission Tomography Computed TomographyAged, 80 and overAdultRadiomics

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenBiomarkers, TumorCD274 protein, human

Autor:innen und Institutionen

  • Onc.AI, San Carlos, CA.
  • Pfizer, Cambridge, MA.
  • University of Pennsylvania, Philadelphia, PA.
  • Moffitt Cancer Center, Tampa, FL.

ORCID-Profile: Chiharu Sako, Chong Duan, Sean Kent, Taly Gilat Schmidt, Ravi B Parikh, George R Simon, Petr Jordan

Zitieren

APA

Sako, C., Duan, C., Maresca, K., Kent, S., Schmidt, T. G., Aerts, H. J. W. L., Parikh, R. B., Simon, G. R., & Jordan, P. (2024). Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00133

Vancouver

Sako C, Duan C, Maresca K, Kent S, Schmidt TG, Aerts HJWL, et al. Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00133

BibTeX
@article{Sako2024,
  author = {Sako, Chiharu and Duan, Chong and Maresca, Kevin and Kent, Sean and Schmidt, Taly Gilat and Aerts, Hugo J W L and Parikh, Ravi B and Simon, George R and Jordan, Petr},
  title = {Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.24.00133}
}
Kostenlos starten →